AstraZeneca has announced plans to invest $50 billion in the US by 2030.  

The main investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the company’s weight-management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small-molecule products. The new center will produce small molecules, peptides, and oligonucleotides. This investment is in addition to the $3.5 billion the company announced in November 2024. 

The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The $50-billion investment across its R&D and manufacturing footprint in the US over the next five years also includes: 

• Expansion of its R&D facility in Gaithersburg, Maryland 

• A new R&D center in Kendall Square, Cambridge, Massachusetts 

• Manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California 

• Continuous manufacturing expansion in Mount Vernon, Indiana 

• Specialty manufacturing expansion in Coppell, Texas 

• New sites to supply clinical trials 

• Growing research and development investment in medicines 

Source: AstraZeneca